{
    "clinical_study": {
        "@rank": "115862", 
        "arm_group": [
            {
                "arm_group_label": "AQW051 10 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "Two 5mg AQW051 capsules will be taken orally daily by patients from Day 1 until Day 84."
            }, 
            {
                "arm_group_label": "Placebo to AQW051", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo administered orally."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study in chronic stable Schizophrenia with the purpose to answer the question of\n      whether agonism of the nicotinic alpha7 receptor is capable of enhancing cognition in a well\n      defined chronic stable patient population treated with antipsychotics as standard of care,\n      and thus to support the future development of AQW051 for the treatment of cognitive\n      impairment associated with Schizophrenia (CIAS)."
        }, 
        "brief_title": "A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of schizophrenia\n\n          -  Symptomatically stable and currently treated with a stable regimen for at least 3\n             (three) months prior to dosing with one of the following second generation of\n             antipsychotics: risperidone, paliperidone, quetiapine, ziprasidone, aripiprazole.\n\n          -  Specific cognitive impairment\n\n          -  Smokers and non-smokers\n\n        Exclusion Criteria:\n\n          -  Current treatment with an anticholinergic or other agent known to adversely interfere\n             with the cholinergic system, and/ or treatment with cholinesterase inhibitor within\n             the last three (3) months prior to dosing.\n\n          -  Current treatment with conventional antipsychotics (e.g fluphenazine, haloperidol) or\n             clozapine.\n\n          -  History of neuroleptic malignant syndrome.\n\n          -  Diagnosis of substance abuse (other than nicotine) within the last month and alcohol\n             or substance dependence (other than nicotine) within the last 6 months.\n\n          -  Score 4 or 5 on the Suicidal Ideation item or any \"yes\" on the Suicidal Behavior item\n             of the CSSR-S that is related to suicidal behavior occurring during the last 2 years\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "147", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730768", 
            "org_study_id": "CAQW051A2207"
        }, 
        "intervention": [
            {
                "arm_group_label": "AQW051 10 mg/day", 
                "intervention_name": "AQW051", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to AQW051", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "schizophrenia, chronic stable schizophrenia, cognition, memory, visual learning, CogState", 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Garden Grove", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92845"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glendale", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91206"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "National City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91950"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94612"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pico Rivera", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90660"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92102"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miramar", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33025"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marlton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08053"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Staten Island", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10312"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Staten Island", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10305"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19131"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Irving", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75062"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to evaluate the pro-cognitive effects of AQW051 in a chronic stable schizophrenic patient population at week 4 as measured by the absolute change from baseline in CPAL number of errors (CogState battery) at week 4.", 
            "measure": "Visual learning and memory at 4 weeks", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730768"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline will be analyzed using a mixed model for repeated measures, including baseline value as covariate, time (timepoint), treatment as fixed effects and treatment*time interaction term and patient as random effect. Appropriate contrasts will be used to compare treatments at each timepoint.", 
                "measure": "Effect on cognitive function after 12 weeks of treatment - CogState test battery.", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks"
            }, 
            {
                "description": "Change from baseline will be analyzed using a mixed model for repeated measures, including baseline value as covariate, time (timepoint), treatment as fixed effects and treatment*time interaction term and patient as random effect. Appropriate contrasts will be used to compare treatments at each timepoint.", 
                "measure": "Effect on cognitive function after 12 weeks of treatment - MCCB", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks"
            }, 
            {
                "description": "Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events and death.", 
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}